# COPE: Cannabinoids to Obviate Pain Experiment After Knee Replacement

> **NCT03675971** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Unity Health Toronto** · enrollment: 220 (estimated)

## Conditions studied

- Arthroplasty, Replacement, Knee

## Interventions

- **DRUG:** Cannabinol
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03675971
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-01
- **Primary completion:** 2021-05-15
- **Final completion:** 2022-05
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2019-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03675971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03675971, "COPE: Cannabinoids to Obviate Pain Experiment After Knee Replacement". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03675971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*